STAT2
Basic information
Region (hg38): 12:56341597-56360203
Links
Phenotypes
GenCC
Source:
- primary immunodeficiency with post-measles-mumps-rubella vaccine viral infection (Supportive), mode of inheritance: AR
- primary immunodeficiency with post-measles-mumps-rubella vaccine viral infection (Strong), mode of inheritance: AR
- pseudo-TORCH syndrome 3 (Strong), mode of inheritance: AR
Clinical Genomic Database
Source:
Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
---|---|---|---|---|---|
Immunodeficiency 44; Pseudo-TORCH syndrome 3 | AR | Allergy/Immunology/Infectious | Individuals with both conditions can demonstrate infection susceptibility, and antiinfectious prophylaxis and early and aggressive treatment of infections may be beneficial; In Immunodeficiency 44, adverse reactions to vaccinations have been reported, and awareness may help prevent morbidity; In Pseudo-Torch syndrome 3, the use of immunologic medical treatments (eg, dexamethasone, ruxolitinib) has been described as showing some benefit; HSCT has been described in Pseudo-Torch syndrome 3 | Allergy/Immunology/Infectious; Biochemical; Renal | 23391734; 26122121; 31836668; 32092142 |
ClinVar
This is a list of variants' phenotypes submitted to
- Primary immunodeficiency with post-measles-mumps-rubella vaccine viral infection (21 variants)
- not provided (2 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the STAT2 gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 97 | 100 | ||||
missense | 185 | 193 | ||||
nonsense | 9 | |||||
start loss | 0 | |||||
frameshift | 12 | 12 | ||||
inframe indel | 6 | |||||
splice donor/acceptor (+/-2bp) | 4 | |||||
splice region | 12 | 26 | 2 | 40 | ||
non coding | 77 | 81 | ||||
Total | 23 | 3 | 193 | 175 | 11 |
Highest pathogenic variant AF is 0.0000131
Variants in STAT2
This is a list of pathogenic ClinVar variants found in the STAT2 region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
12-56343402-G-A | Primary immunodeficiency with post-measles-mumps-rubella vaccine viral infection | Uncertain significance (Dec 09, 2021) | ||
12-56343406-T-C | Primary immunodeficiency with post-measles-mumps-rubella vaccine viral infection | Uncertain significance (Aug 23, 2022) | ||
12-56343408-A-C | Primary immunodeficiency with post-measles-mumps-rubella vaccine viral infection | Uncertain significance (Feb 18, 2022) | ||
12-56343409-A-G | Primary immunodeficiency with post-measles-mumps-rubella vaccine viral infection • STAT2-related disorder | Likely benign (Nov 07, 2023) | ||
12-56343412-G-T | Primary immunodeficiency with post-measles-mumps-rubella vaccine viral infection | Uncertain significance (Aug 03, 2021) | ||
12-56343420-G-C | Primary immunodeficiency with post-measles-mumps-rubella vaccine viral infection | Uncertain significance (Aug 08, 2022) | ||
12-56343420-G-T | Primary immunodeficiency with post-measles-mumps-rubella vaccine viral infection | Uncertain significance (Aug 24, 2021) | ||
12-56343438-C-T | Primary immunodeficiency with post-measles-mumps-rubella vaccine viral infection | Uncertain significance (Aug 15, 2018) | ||
12-56343439-G-A | Primary immunodeficiency with post-measles-mumps-rubella vaccine viral infection | Uncertain significance (Jun 04, 2022) | ||
12-56343443-G-C | Primary immunodeficiency with post-measles-mumps-rubella vaccine viral infection | Likely benign (Mar 13, 2023) | ||
12-56343445-C-T | Primary immunodeficiency with post-measles-mumps-rubella vaccine viral infection • Inborn genetic diseases | Conflicting classifications of pathogenicity (Dec 19, 2023) | ||
12-56343452-C-T | Primary immunodeficiency with post-measles-mumps-rubella vaccine viral infection | Likely benign (Jul 18, 2023) | ||
12-56343454-C-T | Primary immunodeficiency with post-measles-mumps-rubella vaccine viral infection | Uncertain significance (Aug 24, 2021) | ||
12-56343460-C-T | Primary immunodeficiency with post-measles-mumps-rubella vaccine viral infection | Uncertain significance (May 18, 2023) | ||
12-56343467-C-A | Primary immunodeficiency with post-measles-mumps-rubella vaccine viral infection • STAT2-related disorder | Benign/Likely benign (Aug 01, 2024) | ||
12-56343471-C-T | Primary immunodeficiency with post-measles-mumps-rubella vaccine viral infection | Uncertain significance (Oct 25, 2022) | ||
12-56343472-C-A | not specified | Benign (Mar 29, 2016) | ||
12-56343472-CA-AG | Primary immunodeficiency with post-measles-mumps-rubella vaccine viral infection | Benign (Jan 31, 2024) | ||
12-56343473-A-G | not specified • Primary immunodeficiency with post-measles-mumps-rubella vaccine viral infection | Benign (Dec 11, 2023) | ||
12-56343494-C-T | Primary immunodeficiency with post-measles-mumps-rubella vaccine viral infection | Likely benign (Dec 11, 2023) | ||
12-56343495-G-A | Primary immunodeficiency with post-measles-mumps-rubella vaccine viral infection | Uncertain significance (Apr 26, 2023) | ||
12-56343499-T-G | Primary immunodeficiency with post-measles-mumps-rubella vaccine viral infection | Uncertain significance (Aug 17, 2022) | ||
12-56343500-G-A | Primary immunodeficiency with post-measles-mumps-rubella vaccine viral infection | Likely benign (Aug 27, 2023) | ||
12-56343535-G-A | Primary immunodeficiency with post-measles-mumps-rubella vaccine viral infection | Likely benign (Nov 10, 2022) | ||
12-56343811-A-G | Primary immunodeficiency with post-measles-mumps-rubella vaccine viral infection | Likely benign (Dec 24, 2021) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
STAT2 | protein_coding | protein_coding | ENST00000314128 | 23 | 18559 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
0.931 | 0.0694 | 125727 | 0 | 21 | 125748 | 0.0000835 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 2.60 | 299 | 455 | 0.658 | 0.0000248 | 5528 |
Missense in Polyphen | 87 | 153.2 | 0.56788 | 1966 | ||
Synonymous | 1.30 | 160 | 182 | 0.877 | 0.00000936 | 1658 |
Loss of Function | 5.65 | 11 | 57.0 | 0.193 | 0.00000310 | 593 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.000246 | 0.000246 |
Ashkenazi Jewish | 0.00 | 0.00 |
East Asian | 0.000109 | 0.000109 |
Finnish | 0.000277 | 0.000277 |
European (Non-Finnish) | 0.0000704 | 0.0000703 |
Middle Eastern | 0.000109 | 0.000109 |
South Asian | 0.0000327 | 0.0000327 |
Other | 0.00 | 0.00 |
dbNSFP
Source:
- Function
- FUNCTION: Signal transducer and activator of transcription that mediates signaling by type I IFNs (IFN-alpha and IFN-beta). Following type I IFN binding to cell surface receptors, Jak kinases (TYK2 and JAK1) are activated, leading to tyrosine phosphorylation of STAT1 and STAT2. The phosphorylated STATs dimerize, associate with IRF9/ISGF3G to form a complex termed ISGF3 transcription factor, that enters the nucleus. ISGF3 binds to the IFN stimulated response element (ISRE) to activate the transcription of interferon stimulated genes, which drive the cell in an antiviral state (PubMed:9020188, PubMed:23391734). Acts as a regulator of mitochondrial fission by modulating the phosphorylation of DNM1L at 'Ser-616' and 'Ser-637' which activate and inactivate the GTPase activity of DNM1L respectively (PubMed:26122121). {ECO:0000269|PubMed:23391734, ECO:0000269|PubMed:26122121, ECO:0000269|PubMed:9020188}.;
- Disease
- DISEASE: Immunodeficiency 44 (IMD44) [MIM:616636]: An autosomal recessive disorder characterized by increased susceptibility to viral infection, resulting in some patients in encephalopathy and infection-associated neurologic decompensation. {ECO:0000269|PubMed:23391734, ECO:0000269|PubMed:26122121}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
- Pathway
- Kaposi,s sarcoma-associated herpesvirus infection - Homo sapiens (human);Jak-STAT signaling pathway - Homo sapiens (human);Influenza A - Homo sapiens (human);Chemokine signaling pathway - Homo sapiens (human);Necroptosis - Homo sapiens (human);NOD-like receptor signaling pathway - Homo sapiens (human);C-type lectin receptor signaling pathway - Homo sapiens (human);Pathways in cancer - Homo sapiens (human);Hepatitis C - Homo sapiens (human);Hepatitis B - Homo sapiens (human);Measles - Homo sapiens (human);Osteoclast differentiation - Homo sapiens (human);EGFR Inhibitor Pathway, Pharmacodynamics;Human papillomavirus infection - Homo sapiens (human);Herpes simplex infection - Homo sapiens (human);JAK-STAT-Core;Type III interferon signaling;Adipogenesis;Chemokine signaling pathway;The human immune response to tuberculosis;Interferon type I signaling pathways;Type II interferon signaling (IFNG);ifn alpha signaling pathway;Cytokine Signaling in Immune system;JAK STAT MolecularVariation 1;Immune System;IFN alpha signaling;EGFR1;CXCR4-mediated signaling events;JAK STAT MolecularVariation 2;JAK STAT pathway and regulation;Regulation of IFNA signaling;Interferon alpha/beta signaling;IL27-mediated signaling events;Interferon Signaling
(Consensus)
Recessive Scores
- pRec
- 0.357
Intolerance Scores
- loftool
- 0.154
- rvis_EVS
- -0.73
- rvis_percentile_EVS
- 14.14
Haploinsufficiency Scores
- pHI
- 0.524
- hipred
- Y
- hipred_score
- 0.568
- ghis
- 0.587
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- E
- gene_indispensability_score
- 1.00
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Stat2
- Phenotype
- mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); hematopoietic system phenotype; immune system phenotype;
Gene ontology
- Biological process
- regulation of protein phosphorylation;regulation of transcription by RNA polymerase II;JAK-STAT cascade;viral process;cytokine-mediated signaling pathway;defense response to virus;type I interferon signaling pathway;regulation of mitochondrial fission
- Cellular component
- nucleoplasm;cytosol;plasma membrane
- Molecular function
- DNA-binding transcription factor activity, RNA polymerase II-specific;DNA binding;protein binding;identical protein binding;ubiquitin-like protein ligase binding